688136 科興製藥
按盤價 
23.600 +3.050 (+14.842%) | 2026/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2025/12 人民幣(K¥) | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | ||
| 營業總收入 | 607,124 | -13.33% | 1,534,028 | 1,406,925 | 1,259,036 | 1,315,876 | |
| 減：營業總成本 | 707,018 | 8.18% | 1,479,489 | 1,344,390 | 1,531,479 | 1,455,675 | |
| 其中:營業成本 | 278,696 | 9.18% | 561,974 | 440,527 | 367,752 | 324,164 | |
| 財務費用 | 31,649 | 164.21% | 36,496 | 40,855 | 31,185 | 14,924 | |
| 資產減值損失 | (1,518) | 55.17% | (2,342) | (3,669) | (2,562) | (498) | |
| 公允價值變動收益 | 245,633 | 1,490.91% | 79,288 | (29,189) | 239 | (5,351) | |
| 投資收益 | 2,170 | -90.64% | 29,823 | 9,326 | 6,528 | 2,177 | |
| 其中：對聯營企業和合營企業的投資收益 | (10) | -69.94% | (37) | (91) | 23 | -- | |
| 營業利潤 | 146,583 | 70.03% | 168,111 | 63,201 | (256,232) | (138,560) | |
| 利潤總額 | 147,062 | 74.81% | 165,699 | 56,903 | (260,070) | (139,064) | |
| 減：所得稅費用 | 14,584 | 182.29% | 12,955 | 29,854 | (64,583) | (46,240) | |
| 淨利潤 | 132,477 | 67.77% | 152,744 | 27,049 | (195,487) | (92,824) | |
| 減：非控股權益 | (1,465) | 6.03% | (2,823) | (4,432) | (5,196) | (2,529) | |
| 股東淨利潤 | 133,943 | 66.71% | 155,568 | 31,481 | (190,290) | (90,295) | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.680 | 65.85% | 0.790 | 0.160 | -0.960 | -0.450 | |
| 每股派息 (元) * | -- | -- | 0.250 | 0.080 | -- | -- | |
| 每股淨資產 (元) * | 9.132 | 9.25% | 8.700 | 8.189 | 8.163 | 9.101 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 24/08/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
